Intracavitary brachytherapy using tandem and ovoids is an important component of definitive treatment for cervical cancer. In the present study, we analyzed the dose-volume histograms (DVHs) of the tumor volume and organs at risk including the sigmoid colon by CT-based treatment planning for high dose rate (HDR) intracavitary brachytherapy (ICBT) in cervical cancer. Seventeen patients with carcinoma of the cervix uteri were treated with external beam radiotherapy plus concurrent chemotherapy. For brachytherapy, the planning procedure started by performing a conventional plan which prescribed a dose of 6.5-7 Gy per fraction to point A, then optimized the dose based on CT imaging. Volumes and DVHs were calculated for the HR-CTV, bladder, rectum and sigmoid colon. The mean BED2Gy total doses of post-optimized plans of HR-CTV, bladder, rectum and sigmoid colon were: 89.6, 94.1, 74.0 and 69.8 Gy, respectively. For conventional plans, the calculated mean BED2Gy total doses of HR-CTV, bladder, rectum and sigmoid colon were 92.2, 120.1, 75.7 and 78.3 Gy, respectively. This study showed statistical significant higher BED2Gy total doses for bladder and sigmoid colon (p < 0.001) using conventional plans versus post-optimized, CT-based plans, while no difference between HR-CTV and rectum BED2Gy total doses could be detected. After a median follow-up of nineteen months, all seventeen patients had a clinical complete response. Two patients developed distant metastasis. Compared with conventional treatment, CT based brachytherapy planning was very effective in reducing doses to OARs, especially bladder and sigmoid colon whilst maintaining a high therapeutic dose for tumor target volumes in the treatment of cervical carcinoma.
INTRODUCTION
Carcinoma of the uterine cervix is the most common malignancy in Thai women. 1) Based on large randomized trials, the standard treatment of locally advanced cervical carcinoma is defined as concurrent cisplatin-based chemotherapy and radiotherapy. [2] [3] [4] However, intracavitary brachytherapy (ICBT) is still an important part of radiation treatment for patients with locally advanced carcinoma of the cervix. The major advantage of ICBT is that high radia-tion doses can be built up in tumors while sparing the adjacent normal organ tissues. 5) For conventional brachytherapy planning, simple orthogonal X-rays are usually obtained to evaluate the position of the applicator in relation to musculoskeletal pelvic anatomy and the dose is prescribed to a fixed reference point 2 cm superior and 2 cm lateral to the distal end of the applicator/tandem (Point A), regardless of tumor characteristics or the individual patient anatomy. 6) Although x-ray based planning yielded promising clinical results, the problem of mismatch to the real geometry of the target volumes in film-based planning caused limitations in terms of optimization. CT-based conformal external beam radiotherapy planning is nowadays widely used in the majority of radiotherapy facilities, although brachytherapy treatment planning based on 3D images is still not standard. However, interest in image-guided brachytherapy is increasing and more facilities have started to implement this new planning technique in order to optimize and individualize treatment planning for each patient. This has the potential of substantial improvement in long-term outcomes in women with cervical cancer. 7) This positive trend may turn out to be of great importance especially in countries with high incidence of this specific malignant entity. The technology allows radiation oncologists and medical physicists to adjust the dose distribution, and to both conform to the tumor target volume and reduce the dose to normal tissues. Using this approach, it might be possible to decrease the probability of normal tissue toxicity and to escalate the dose to the tumor in order to produce better rates of local control. Recently, European guidelines for three-dimensional ICBT for cervical cancer (Groupe Européen de Curiethérapie -European Society for Therapeutic Radiology and Oncology [GEC-ESTRO]) have been published. 8, 9) This approach enables dose prescription on contoured targets and allows dose evaluation based on dose-volume parameters, both for target and organs at risk (OARs). GEC-ESTRO provided recommendations for target delineation using magnetic resonance imaging (MRI) contoured tumor volumes, and distinct definitions were proposed for the gross tumor volume (GTV), the highrisk clinical target volume (HR-CTV) and the intermediaterisk clinical target volume (IR-CTV). Computed tomography (CT) is widely used for diagnostic and radiotherapeutic procedures. Anatomic-morphologic imaging details and 3D density information from CT improves the quality of radiotherapy planning and treatment. In our department, a CT scanner was recently installed for specific use as a dedicated simulator and for implementing systematically 3D conformal radiotherapy/brachytherapy planning. According to GEC-ESTRO recommendations, Viswanathan et al. proposed in 2007 guidelines for CT-based brachytherapy planning in cervical cancer. 10) In our institution, the GEC-ESTRO recommendations of volume-based planning according different imaging options (MRI and/or CT) were systematically introduced. This was to evaluate their benefits and feasibility in the context of a university hospital radiotherapy department work-flow for a regional high-volume tumor entity. In consequence, this study aimed to evaluate prospectively the dose delivered to the tumor target (especially HR-CTV) and OARs in cervical cancer patients treated with external beam radiotherapy and CT-based HDR-intracavitary brachytherapy in comparison with conventional planning.
MATERIALS AND METHODS
From July 2008 to April 2010, twenty-two consecutive patients with cervical cancer were referred for definitive treatment by radio-chemotherapy according to the department protocol during the study time. Radiotherapy consisted of external beam radiotherapy and CT-based HDR-ICBT. Eligibility trial entrance criteria were: histologically confirmed cervical carcinoma, FIGO stages IB to IIIB, Karnofsky performance status ≥ 50, age at diagnosis 20-60 years, no emergency condition, no history of allergy (contrast media or chemotherapy), and informed consent. Patients aged > 60 years, metastatic disease, poor underlying conditions, allergy to used chemotherapy agents or contrast media, or Karnofsky performance status less than 50 were excluded from the study. Treatment composed of external beam radiation therapy (EBRT) 50 Gy in 25 fractions and 4 brachytherapy (BT) fractions of 6.5-7 Gy. Five out of twenty-two patients were excluded due to emergency conditions (eg. severe bleeding during external beam irradiation) thereby the CT procedure was not feasible. Thus, seventeen patients entered the study and could be evaluated. Median age was 50 years (range 36-60). One, twelve and four patients were in FIGO stage IB2, IIB, IIIB, respectively. Patient characteristics are detailed in Table 1 .
Chemotherapy
Concomitant chemotherapy with weekly cisplatin 40 mg/m 2 or carboplatin in Area Under Curve (AUC) [according to Calvert' s formula] 11) equal to two for a maximum of six courses was given to patients with indications of combined chemoradiotherapy with sufficient kidney and bone marrow function. The dose of chemotherapy was modified according to a weekly assessment of creatinine clearance prior to each applied dose. 
External Beam Radiotherapy
The patients received whole pelvic 3D conformal EBRT using a four-field box technique with individual blocks based on CT-assisted 3D treatment planning. The primary gross tumor volume (GTV) was defined determined by joint information from the CT scan, physical examination, and other staging imaging. The clinical target volume (CTV) was defined as an area of potential microscopic disease and included the gross tumor volume, whole cervix, entire uterus, parametrial tissue, 2 cm of the upper vagina, common iliac nodes, external iliac nodes, internal iliac nodes, obturator nodes, and pre-sacral lymph nodes. The lymph node groups were contoured according to the recommendations of Taylor et al. 12) The prescribed dose of EBRT to the CTV was 50 Gy in 25 fractions with 3 cm-midline block at 30-46 Gy. The parametrium was boosted to 56 Gy when involving a tumor. A 6-10 MV photon beam from a linear accelerator was used.
Brachytherapy
Fractionated remote-controlled HDR-ICBT was performed using a stepping Iridium-192 source and a standard Fletcher type tandem-ovoid applicator or a CT/MR applicator. A Foley's catheter was placed in the bladder and inflated with 7 cc of diluted contrast media. A normal saline solution (50 cc) plus 10 cc of contrast media were added into the bladder to identify bladder volume on planning imaging. The vagina was packed with gauze to increase the distance between the radiation source, and the rectum/bladder. HDR-ICBT was performed in four fractions, started after three weeks of EBRT initiation. EBRT was interrupted for each day of HDR brachytherapy insertion. After tandem-ovoid application, all patients were transferred to CT, and the pelvic region from the iliac crest to the ischial tuberosity was scanned without intravenous contrast to obtain appropriate images with the patients in supine treatment position and legs relaxed on the table. The slice thickness of CT scans was 5 mm without an inter-slice gap. After the CT scan was performed, the position of the applicators was checked and imaging data was collected by the radiation oncologist before transferred to the planning system. Patients were then transferred to the brachytherapy treatment room and adjusted to the same position as in the CT simulator. The treatment planning procedure started with the generation of a standard plan normalized to point A. The prescribed dose for each fraction of HDR brachytherapy was 6.5-7 Gy. Computer assisted 3D treatment planning for brachytherapy based on CT was then performed in all patients. The study enrolled patients were treated with the CT-based optimized brachytherapy plan.
Contouring of tumor volumes and organs at risk
Data were transferred from the CT scanner into the planning system via an ethernet connection. Tumor target and organs at risk (OARs) were contoured in each axial CT image. Delineation of high risk clinical target volume (HR-CTV) was performed based on CT information at the time of brachytherapy supported by further available clinical findings. All target volumes and OARs were contoured according to the CT-standardized Contour Guidelines of Viswanathan et al. 10) (See also Fig. 1 ) High-risk clinical target volume (HR-CTV) was defined by the volume carrying a high probability of tumor spread: the whole cervix and the presumed extracervical tumor extension at the time of brachytherapy. Intermediate-risk clinical target volume (IR-CTV) was defined by the volume carrying a significant probability of microscopic tumor spread encompassing the HR-CTV with a safety margin of 5-15 mm. OARs were defined as bladder, rectum and sigmoid colon. The rectum was contoured from the anal-rectal to the rectosigmoid junction. Delineation of the sigmoid colon started at the rectosigmoid junction and ended 2 cm above the uterus. Bladder was contoured as an entire organ.
Treatment planning for CT-based conformal 3D brachytherapy
After CT-simulation and contouring of target volumes/ OARs was completed, the treatment planning was performed using the PLATO planning system (Software BPS version 3.3.2, Eval version 3.0, Nucletron B.V., Veenendaal, Netherlands). Each brachytherapy fraction was planned individually and was first initiated by calculating a standard plan, which contained for both side ovoids three stopping positions spaced by 5 mm in each side. For the tandem, the stopping positions were placed at a 5 mm distance from the tip to the level of the guard ring. For the standard plan, equal dwell times were used in all stopping positions in the oviods and the tandem applicators. The prescribed dose was 6.5-7 Gy × 4 fractions to point A (ICRU 38) in all patients, corresponding to a prescribed dose of 80 Gy BED2Gy. The optimization procedure was performed by manually adding or removing stopping positions and adjusting the dwell times for each given position of the stepping source. The system graphic optimization tool was also used to enable the optimization of dose distribution by dragging/adjusting isodose lines. Dose-volume histograms (DVHs) were calculated for the HR-CTV, rectum, bladder, and sigmoid colon.
CT based 3D final optimization and dose-volume histogram analysis
The objectives of the CT based final optimization were: 1) to reduce the dose to the critical normal organs at risk in order to meet the defined dose constraints, and 2) to possibly increase the tumor target dose. For the target volume (HR-CTV), we focused primarily on D90 values in our analysis. In the D90, the minimum dose covering 90% of the HR-CTV, is considered to be a more stable parameter than the D100 due to decreased sensitivity to variations in contouring. 9) The D90 was derived from the cumulative dosevolume histogram (DVH) analysis. The dose delivered to the OARs was evaluated using the DVH parameters representing the minimum doses calculated at the most irradiated 2 cc volumes (D2cc). The resulting dose was calculated into the equivalent dose in 2-Gy fractions (BED2Gy) using the linearquadratic model and assuming α/β ratio = 10 for tumor and α/β = 3 for OARs. Doses were normalized using this formalism and were denoted by Gy α/β3 (critical normal organs) or Gy α/β10 (target HR-CTV). The BED2Gy of EBRT and brachytherapy were added to evaluate the optimized plan with regard to the DVH constraints. For the HR-CTV, we aimed to achieve a total D90 ≥ 80 Gyα/β10. Dose constraints for the OARs, total D2cc were 75 Gyα/β3 for rectum and sigmoid colon and 90 Gyα/β3 for the bladder, respectively.
Follow-up schedule and toxicity assessment
After completion of the treatment protocol, the follow-up schedule for patients included monthly physical and pelvic examinations for the first three months, and was repeated every three months for one year, every four months for the second year, every six months for another third year and then annually. Side effects -acute (within 90 days) were assessed at time of each evaluation with cooperative group common terminology criteria of adverse events (CTCAE) of National Cancer Institute (NCI) version 3.0. The late toxicities were evaluated by RTOG/EORTC late morbidities criteria.
Statistics
All continuous numerical variables were presented as mean values with standard deviations or with minimum and maximum values (range). The difference of DVH parameters were assessed using paired t-test, and a value of p < 0.05 was considered significant. SPSS software (version 16.0 for Windows) was used for the analyses.
RESULTS
Seventeen patients with locally advanced cervical cancer entered this study and were analyzed. At the median follow up of 19 months (range 7-35 months), all 17 patients had no local recurrence at the primary site. Two patients developed distant metastases. One patient developed a pulmonary metastasis and was treated with palliative chemotherapy. The second patient developed left supraclavicular lymph node metastasis after one year of treatment. The patient was treated with palliative chemotherapy and died tumor-related one year later.
Comparison of standard versus 3D conformal plans
The doses of HR-CTV (D90), bladder (D2cc), rectum (D2cc) and sigmoid colon (D2cc) for the CT-based 3D optimized plans were calculated, and compared with the initial calculated standard plans. Finally, the optimized plans were applied to the patient. The mean BED 2Gy total doses of postoptimized plans of HR-CTV, bladder, rectum and sigmoid colon were: 89.6, 94.1, 74.0 and 69.8 Gy, respectively. For conventional plans, the calculated mean BED 2Gy total doses of HR-CTV, bladder, rectum and sigmoid colon were 92.2, 120.1, 75.7 and 78.3 Gy, respectively. This information is summarized in Table 2 and Fig. 2.   Fig. 1 . CT imaging of patients with applicator, high-risk clinical target volume (HR-CTV: light blue line) and Organs at risk (bladder and rectum). The 150%-, 100%-and 50%-isodose lines were shown in yellow, red and green colors, respectively. 
Toxicity Profile
Toxicity was assessed according CTCAE version 3.0. No patients developed acute severe side effects during treatment. In terms of severe late toxicity one patient with stage IIIB disease developed a rectovaginal fistula at distal twothirds of the vagina one year after treatment (the biopsy showed no malignancy) and one patient with stage IIB had intermittent rectal bleeding (grade 3 rectal toxicity). Detailed toxicity data is shown in Table 3 .
DISCUSSION
Brachytherapy allows a high dose deposition to the primary tumor while minimizing the dose to adjacent normal organs. Thus, brachytherapy plays an important role in the treatment of cervical cancer. In this report, we have described our preliminary experience using image-based conformal 3D brachytherapy and have demonstrated the feasibility of maintaining target coverage while substantially reducing the dose to adjacent critical normal organs. In the present study, CT-based treatment planning provided detailed anatomical data for both tumor and normal tissue volumes, and allowed for true 3D plan optimization. Dosimetric analyses showed statistically significant differences in favor of CT-based 3D optimized plans versus conventional planning, and indicated that dose levels especially to the bladder, and sigmoid colon were substantially reduced.
A key development for initiation of modern conformal planning techniques for brachytherapy represented the GEC-ESTRO release of guidelines for image-based brachytherapy in 2005/2006 which proposed three dimensional volume concepts based on modern imaging and dose volume histograms of target volume and organs at risks. 8, 9) This led to a convergence of development in brachytherapy to the existing standard of photon external beam radiotherapy. Since this advent the use of image-guided brachytherapy was tested and introduced in specialized centers. With 3D conformal planning benefits in terms of reducing the dose to OARs and improving dose to the target could be demonstrated, 7, 8) which was in concordance to the findings of the present study. Pötter et al. showed the impact of MRI-guided brachytherapy in cervical cancer. 7) Image-guided brachytherapy could improve local control and reduce treatmentrelated toxicity. Overall survival (OS) was 58%, and cancerspecific survival (CSS) was 68% at three years. In two different consecutive periods of development, OS improved further from 53% to 64% (p = 0.03) and in CSS from 62% to 74% (p = 0.13). However, improvement occurred only in tumors > 5 cm: OS 28% versus 58% (p = 0.003); CSS 40% versus 62% (p = 0.07). The actuarial late morbidity rate (grades 3 and 4) at three years was low with 4% for gastrointestinal and 4% for the urinary system, respectively. Tan et al. demonstrated a three year cancer specific survival rate of 81%, with a very high pelvic control rate of 96% using image-based conformal brachytherapy. In 24 patients, a D90 > 74 Gy (a/β10) was achieved. A single patient with a local recurrence had a D90 of 63.8 Gy (α/β10). 13) However, the overall actuarial risk of serious late morbidity was higher than in the series of Potter et al. with 14%. Zwahlen et al. reported the use of MRI-guided brachytherapy in cervical carcinoma. 14) In 20 patients, the study showed that HR-CTV and IR-CTV were optimally treated in 70% and 85% of the patients with conventional plans, and in 75% and 95% of the patients with optimized plans, respectively. Furthermore, the authors could demonstrate diminished minimal doses to the contiguous 2-cc of the rectum, sigmoid, and bladder of 12-32% difference in favor of 3D planning versus conventional BT planning. With MRI-guided BT optimization, it was possible to both maintain coverage of the HR-CTV/IR-CTV and reduce the dose to the normal tissues, especially in patients with small tumors at BT.
Our study demonstrated a clear advantage of image-guided brachytherapy versus conventional planned BT as well as showing significantly reduced doses for bladder (p < 0.001; D2cc 94.1 versus 120.1 Gyα/β3) and sigmoid (p < 0.001; D2cc 69.8 versus 78.3 Gyα/β3), while no disadvantage in coverage of HR-CTV (p = 0.16; D90; 89.6 versus 92.2 Gyα/β10) and rectum (p =0.29; D2cc 74 Gy versus 75.7 Gyα/β3) could be registered. These parameters were similar to the results of the Vienna study (Dimopoulous et al.), which showed good clinical response at an equivalent dose BED2Gy at D90 for HR-CTV more than 86 Gy. 15) Discussed studies using image-guided conformal brachytherapy for cervical cancer are listed and detailed in Table 4 .
The present study showed no grade 3 or 4 acute side effects. Only grade 1 and 2 acute morbidity was registered. In terms of late toxicity, we observed no grade 3 and 4 genitourinary toxicity, however, one patient experienced grade 7, 13) Obviously, we recognize the limitations of the relatively small number of patients enrolled in the present trial and the lack of long-term follow-up. However, all treated patients in the trial will be systematically followed.
The implementation of this study changed the routines in our department in terms of work-flow. The entire process of CT-based brachytherapy planning proved to be feasible and workable. With CT-based planning, the total duration from initiation to the end of the process was approximately two hours in comparison with the conventional film-based planning of ca. 0.5-1 hours. Generally, the planning procedure was well tolerated. Additional oral analgesia was only exceptionally required.
In summary, image-based brachytherapy techniques allow us to precisely identify HR-CTV and OARs. Dose optimization and corrections in cases of inadequate target coverage and/or unacceptable high doses to OARs are enabled. Sigmoid colon as an important additional OAR cannot be sufficiently evaluated in conventional planning and is generally underestimated, but should be of concern in 3D-based planning, because overdosing the sigmoid can also lead to serious long-term sequelae. DVHs of volume-based planning provide us with additional important information and help us to optimize the dose distribution in all target volumes and OARs. However, our study results are preliminary in order to conclude that 3D-based brachytherapy is generally superior in comparison with conventional planning.
In conclusion, the present study was very effective by using CT based brachytherapy planning in order to significantly reduce doses to OARs, especially bladder and sigmoid colon, and maintain a high therapeutic dose for tumor target volumes compared with conventional planning in the treatment of cervical carcinoma. The preliminary findings in terms of acute and late toxicity were very promising as well. No tumor relapse was registered at 19 months follow-up. 
